Abstract
Background The marginal benefit of ethanol infusion into the VOM as an adjunct to atrial fibrillation ablation has shown promise in a single randomized study and case series from very experienced centers. However, adoption has not been widespread and the impact on real-world outcomes outside of leading centers is not established.
Objective To understand the learning curve, and explore procedural outcomes and safety with VOM ethanol infusion from a large single medical center.
Methods All atrial ablation cases wherein VOM ethanol infusion was attempted were identified from the time of the program’s inception in 2019 at Maine Medical Center (Portland, ME). Our technical approach, procedural success and efficacy rates, and complications were adjudicated from the medical record.
Results The overall VOM ethanol infusion success was 90%. Infusion success rates improved and fluoroscopy utilization decreased with experience. Arrhythmia recurrence was 86% after a mean follow-up of 9.5 months, with an arrhythmia-freedom probability of 80% at 12 months. Complications occurred in 5.4% of patients, including a 3.1% risk of delayed tamponade.
Conclusion In our single center experience, VOM ethanol infusion was feasible with a high technical success rate and excellent arrhythmia freedom in follow-up. These positive results are balanced against a concerning rate of delayed tamponade.
Competing Interest Statement
J.L.M. has received speaking fees from Sanofi.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Maine Medical Center Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Compliance with Ethical Standards
Conflict of interest: J.L.M. has received speaking fees from Sanofi Aventis. The remaining authors have no relevant financial or non-financial interests to disclose.
Funding: The authors did not receive support from any organization for the submitted work.
Ethical approval: This study was approved by the Maine Medical Center Institutional Review Board and performed in accordance with the Declaration of Helsinki.
Informed consent: This is a retrospective study performed by chart review and as such, informed consent was waved by the Institutional Review Board.
Data Availability
Data produced for the purposes of tables and figures and published in this article is available upon reasonable request to the authors. Any additional clinical details are maintained confidential.
